Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004

Cancer ◽  
2008 ◽  
Vol 113 (4) ◽  
pp. 791-798 ◽  
Author(s):  
Yuhong Zhou ◽  
Haijun Wang ◽  
Wenjing Fang ◽  
Jorge E. Romaguer ◽  
Yanxia Zhang ◽  
...  
Keyword(s):  
United States ◽  
Mantle Cell Lymphoma ◽  
Cell Lymphoma ◽  
The United States ◽  
Incidence Trends ◽  
Mantle Cell

scholarly journals Cost-effectiveness for KTE-X19 CAR T therapy for adult patients with relapsed/refractory mantle cell lymphoma in the United States

2021 ◽  
Vol 24 (1) ◽  
pp. 421-431
Author(s):  
Claire L. Simons ◽  
Daniel Malone ◽  
Michael Wang ◽  
Gregory A. Maglinte ◽  
Tim Inocencio ◽  
...  
Keyword(s):  
United States ◽  
Cost Effectiveness ◽  
Mantle Cell Lymphoma ◽  
Cell Lymphoma ◽  
The United States ◽  
Adult Patients ◽  
Car T ◽  
Mantle Cell

Survival trends in mantle cell lymphoma in the United States over 16 years 1992–2007

2012 ◽  
Vol 53 (8) ◽  
pp. 1488-1493 ◽  
Author(s):  
Rekha Chandran ◽  
Stuart K. Gardiner ◽  
Miklos Simon ◽  
Stephen E. Spurgeon
Keyword(s):  
United States ◽  
Mantle Cell Lymphoma ◽  
Cell Lymphoma ◽  
The United States ◽  
Mantle Cell

Trend and Geographic Variations in the Incidence of Mantle Cell Lymphoma in the United States over 30 Years from 1975 to 2004.

Blood ◽  
2007 ◽  
Vol 110 (11) ◽  
pp. 4414-4414
Author(s):  
Yuhong Zhou ◽  
Haijun Wang ◽  
Xin Du ◽  
Qing Yi ◽  
Yanxia Zhang ◽  
...  
Keyword(s):  
United States ◽  
African Americans ◽  
Mantle Cell Lymphoma ◽  
Cell Lymphoma ◽  
The United States ◽  
Geographic Variations ◽  
Annual Increase ◽  
Geographical Variations ◽  
Mantle Cell ◽  
Adjusted Incidence

Abstract Background: Mantle cell lymphoma (MCL) is an uncommon subtype of non-Hodgkin’s lymphoma (NHL). To better understand the incidence and epidemiological features of MCL in the United States, we conducted a population-based study with 2635 patients (pts) of MCL identified from 9 Surveillance, Epidemiology, and End Results (SEER) tumor registries over 30 years. Methods: From SEER public database, we identified 111 424 pts of all ages diagnosed with NHL between 1975 and 2004 in 9 SEER areas. Of these pts, 2635 had histologically confirmed MCL, accounting for 2.36% of NHL. The incidence with 95% confidence intervals were generated from SEER*Stat Software. Incidence was age-adjusted to the U.S. 2000 standard population. Annual percent change (APC) for the incidence was calculated and considered to be statistically significant if P<0.05. The crude 1-year survival rate was calculated as the ratio of the number of pts who survived over 1 year and the number of pts diagnosed with MCL. Results: Of 2,635 pts with MCL, 68.1% were late-stages (stages III IV), 25.6% were early-stages (stages I–II), and 6.3% were unstaged. Median age at diagnosis for MCL was 68.0. Overall incidence was 0.41/100,000/year, which increased by age from 0.06 in pts aged <50 to 2.11 for 70–79 and 2.02 in pts aged 80 or older. The age-adjusted incidence increased from 0.08 in 1975 to 0.67 in 2004. APC was 4.64% (P<0.05). Incidence of MCL was higher in men (0.60) than in women (0.27) (P<0.05). Annual increase was greater in men (5.67%) than in women (2.93%). There were also substantial geographic variations (P<0.05) in the incidence of MCL. The age-adjusted incidence was highest in Seattle (0.49) and the lowest in Hawaii (0.33). The incidence appeared to be higher in Caucasians (0.44) than in African-Americans (0.25) and other races (0.25). Annual increase(from 1987–2004) was 8.68% in Caucasians, and 1.64% in African-Americans and other races. Conclusions: The incidence of MCL increased progressively from 1975 to 2004, and was significantly higher in males and in Caucasians. There were substantial geographical variations in the incidence of MCL.

Sign in / Sign up

Export Citation Format

Share Document